Moreover, KEAP1 point mutations were identified in several human cancers such as gastric (11.1%), liver (2–8%), colorectal (7.8%), prostate (1.3%), gallbladder (30.7%), ovarian (37%), glioma (1.7%), head and neck (42%), and clear renal cell carcinoma (4.7%) [19–29]. This evidence concerns the gene KEAP1 and clear cell renal carcinoma.